This Article Full Text Full Text (PDF) Erratum (v25,p4030) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liberato, N. L. Articles by Barosi, G. Search for Related Content PubMed PubMed Citation Articles by Liberato, N. L. Articles by Barosi, G. Related Articles Related Editorial Related Correspondence Related Article

Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Nicola Lucio Liberato, Monia Marchetti, Giovanni Barosi

From the Azienda Ospedaliera della Provincia di Pavia, Divisione di Medicina Interna, Ospedale Civile, Casorate Primo; and Laboratorio di Epidemiologia Clinica, Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico S Matteo, Pavia, Italy

Address reprint requests to Nicola Lucio Liberato, MD, Divisione di Medicina Interna, Ospedale Civile "C. Mira", 27022 Casorate Primo, Pavia, Italy; e-mail: lucio_liberato{at}ospedali.pavia.it

PURPOSE: To evaluate the cost-effectiveness of 12-month adjuvant trastuzumab therapy in women with high-risk human epidermal growth factor receptor 2 (HER2) –positive early breast cancer.

METHODS: A Markov model tracked quarterly patients’ transitions between five health states: disease free, local relapse, disease free after local relapse, metastatic disease, and death. Patients were allowed to incur symptomatic or asymptomatic transient cardiac dysfunction during trastuzumab administration. Probabilities were derived mainly from the combined report of the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 trials (95% node positive) and a meta-analysis by the Early Breast Cancer Trialists’ Collaborative Group. Costs were estimated from the perspective of the Italian and US health care systems. The analysis was run during a 15-year time horizon. A 3% yearly discount rate was applied to both costs and life-years. Second-order Monte-Carlo and probabilistic sensitivity analyses were performed.

RESULTS: Adjuvant trastuzumab increases life expectancy by 1.54 (1.18 discounted) quality-adjusted life-years (QALYs). At a cost of 675 and $767 per weekly dose in the Italian and US setting, respectively, trastuzumab achieves its clinical benefit at a cost of 14,861 (95% CI, 3,917 to 44,028) and $18,970 (95% CI, $6,014 to $45,621) per QALY saved. The incremental cost effectiveness was higher than 50,000/QALY (or $60,000/QALY) at time horizons shorter than 7.8 years and for patients older than 76 years or with a 10-year risk of relapse lower than 15%. The results confirmed the cost effectiveness when simulating a Herceptin Adjuvant Trial (HERA) -like scenario at multiway sensitivity analysis.

CONCLUSION: In a long-term horizon, adjuvant trastuzumab is a cost-effective therapy for patients with HER2-positive, high-risk, early breast cancer.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Related Editorial

• Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab?
  Bruce E. Hillner and Thomas J. Smith
  JCO 2007 25: 611-613 [Full Text]

Related Correspondence

• Health Economics in the Journal of Clinical Oncology and an Evaluation of the Indirect Costs and Benefits Associated With Adjuvant Trastuzumab
  Gilberto de Lima Lopes, Jr and Stefan Gluck
  JCO 2007 25: 3382-3383 [Full Text]

Related Article

• Health Economics in the Journal of Clinical Oncology and an Evaluation of the Indirect Costs and Benefits Associated With Adjuvant Trastuzumab
  Gilberto de Lima Lopes, Jr and Stefan Gluck
  JCO 2007 25: 3382-3383 [Full Text]

This article has been cited by other articles:

				R. MacKenzie, S. Chapman, G. Salkeld, and S. Holding Media influence on Herceptin subsidization in Australia: application of the rule of rescue? J R Soc Med, June 1, 2008; 101(6): 305 - 312. [Abstract] [Full Text] [PDF]

				M. Lidgren, B. Jonsson, C. Rehnberg, N. Willking, and J. Bergh Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer Ann. Onc., March 1, 2008; 19(3): 487 - 495. [Abstract] [Full Text] [PDF]

				G. de Lima Lopes Jr and S. Gluck Health Economics in the Journal of Clinical Oncology and an Evaluation of the Indirect Costs and Benefits Associated With Adjuvant Trastuzumab J. Clin. Oncol., August 1, 2007; 25(22): 3382 - 3383. [Full Text] [PDF]

				N. J. Meropol and K. A. Schulman In Reply J. Clin. Oncol., August 1, 2007; 25(22): 3383 - 3383. [Full Text] [PDF]

				B. E. Hillner and T. J. Smith Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab? J. Clin. Oncol., February 20, 2007; 25(6): 611 - 613. [Full Text] [PDF]

				M. N. Levine, P. A. Ganz, and D. G. Haller Economic Evaluation in the Journal of Clinical Oncology: Past, Present, and Future J. Clin. Oncol., February 20, 2007; 25(6): 614 - 616. [Full Text] [PDF]